Robbins LLP is Investigating Allegations that PROCEPT BioRobotics Corporation Inflated the Company's Reported U.S. Headpiece Unit Sales and Revenues

Robbins LLP informs investors that a securities class action has been filed on behalf of all purchasers of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) common stock between February 28, 2024 and February 25, 2026, inclusive (the "Class Period"). Investors who suffered significant losses during the Class Period may be eligible to participate in the lawsuit and should contact Robbins LLP for information about becoming lead plaintiff Investors who suffered significant losses during the Class Period may be eligible to participate in the lawsuit and should contact Robbins LLP for information about becoming lead plaintiff.

Why Was PROCEPT Sued?

The complaint alleges that PROCEPT made materially false or misleading statements regarding its business, operations, and financial condition during the Class Period.

Specifically, the lawsuit alleges that the Company:

• utilized an extensive discount program designed to incentivize its customers to place bulk orders in excess of procedure demand;
• had an undisclosed discount program that artificially and unsustainably inflated the Company’s reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods;
• caused customer handpiece orders to materially exceed underlying procedure demand throughout the Class Period and that this differential had materially grown over time;
• had a consistent surplus of U.S. handpiece unit sales relative to performed procedures that created a glut of field inventory and overstocking amongst PROCEPT’s customer base, amounting to more than 10,000 excess units by the end of the Class Period;
• materially overstated PROCEPT’s handpiece unit sales and the utilization of PROCEPT’s field Systems;
• was acutely exposed to material undisclosed risks of significant operational and financial harm; and
• was unable to achieve its stated 2025 handpiece sales and revenue guidance and such guidance lacked a reasonably achievable factual basis.

What Happened?

On August 6, 2026, PROCEPT announced second quarter 2025 earnings, revealing that headpiece unit shipments had unexpectedly deteriorated and reducing next quarter's consensus estimates by 500 units.

On November 4, 2025, PROCEPT announced third quarter 2025 earnings results, revealing that handpiece unit sales had missed the already disappointing sales guidance issued during the prior quarter. During the corresponding conference call, defendant Waters further revealed that PROCEPT was reducing its annual handpiece sales guidance by 1,000 units to allow for the “optimization of field inventory.”

Then, on February 25, 2026, PROCEPT announced fourth quarter earnings results, disclosing the number of actual procedures performed in the field over the prior three years. The previously undisclosed data revealed that U.S. handpiece unit sales had materially exceeded procedures in every quarter since the first quarter of 2023, resulting in cumulative excess field inventory of more than 10,000 units. The Company also indicated it was eliminating its longstanding, previously undisclosed discount program designed to incentivize customers to place bulk orders at the end of each quarter, which had negatively impacted headpiece sales.

On this news, the price of PROCEPT common stock fell from $27.84 per share on February 25, 2026 to $22.69 per share on February 27, 2026, a decline of more than 18% over a two-day trading period. The price of PROCEPT stock has continued to decline as the negative impacts of PROCEPT’s undisclosed discounting program and customer overstocking problems have been revealed to the market, falling to less than $18 per share by July 22, 2026.

Are You Eligible: The lawsuit seeks to represent investors who purchased or otherwise acquired PROCEPT securities during the period from February 28, 2024 and February 25, 2026. Investors who suffered losses during that period may have legal rights under the federal securities laws. Submit a form for information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.